2. Search Result
Search Result
Results for "

Carbon Activated

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-Y1213
    Carbon

    Carbon Activated

    		 Biochemical Assay Reagents Others Cancer
    Carbon can be used as an excipient, such as decolorizer. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
    Carbon
  • HY-W048457
    Palladium hydroxide on activated carbon(20%)(wetted with ca. 55% Water)

    Pearlman's Catalyst (contains Pd, PdO) (wetted with ca. 55% Water)

    		 Biochemical Assay Reagents Others
    Palladium hydroxide on activated carbon(20%)(wetted with ca. 55% Water) is a biological molecule.
    Palladium hydroxide on activated carbon(20%)(wetted with ca. 55% Water)
  • HY-113037C
    Farnesyl pyrophosphate ammonium

    Farnesyl diphosphate ammonium

    		 TRP Channel Endogenous Metabolite Neurological Disease
    Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
    Farnesyl pyrophosphate ammonium
  • HY-130239
    14(S)-HDHA

    14(S)-HDoHE

    		 Drug Metabolite Neurological Disease
    14(S)-HDHA (14(S)-HDoHE) is an oxygenation product of Docosahexaenoic acid (DHA). 14(S)-HDHA is a marker reflecting activation of a Docosahexaenoic acid carbon 14-lipoxygenation pathway .
    14(S)-HDHA
  • HY-172816
    Carbonic anhydrase inhibitor 32

    		Carbonic Anhydrase mTOR NKCC Neurological Disease
    Carbonic anhydrase inhibitor 32 (compound 5B) is an orally active and selective hCA (Carbonic anhydrase ) II/VII inhibitor with the Ki values of 6.3 nM, 10.1 nM and 681 nM for hCA II, hCA VII and hCA I,respectively. Carbonic anhydrase inhibitor 32 shows neuroprotective and anticonvulsant potential by reducing mTOR activation, and raising hippocampus KCC2 levels .
    Carbonic anhydrase inhibitor 32
  • HY-121465
    Stearoyl Serotonin

    		Endogenous Metabolite Metabolic Disease
    Stearoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin. Arachidonoyl serotonin is a dual antagonist of fatty acid amide hydrolase (FAAH) and the transient receptor potential vanilloid-type 1 (TRPV1) channel, reducing both acute and chronic peripheral pain. The effects of replacing the arachidonoyl portion with the saturated 18-carbon stearoyl moiety have not been studied. However, replacement of arachidonate with saturated 11- or 12-carbon fatty acids produces compounds that potently inhibit capsaicin-induced TRPV1 channel activation (IC50=0.76 μM) without blocking FAAH-mediated hydrolysis of arachidonoyl ethanolamine (IC50 > 50 μM).
    Stearoyl Serotonin
  • HY-W440954
    Stearic acid-PEG-CH2CO2H, MW 2000

    		Liposome Others
    Stearic acid-PEG-CH2CO2H, MW 2000 is a heterobifunctional polyPEG with 18-carbon aliphatic chain and carboxyl. The polymer has stearic acid as the hydrophobic tail and PEG as the hydrophilic chain, therefore it forms micelles in water. Carboxyl can react with amine in the presence of activator, such as HATU/EDC to generate a stable amide bond. Reagent grade, for research use only.
    Stearic acid-PEG-CH2CO2H, MW 2000
  • HY-113037
    (E/Z)-Farnesyl pyrophosphate

    (E/Z)-Farnesyl diphosphate

    		 TRP Channel Endogenous Metabolite Neurological Disease
    (E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
    (E/Z)-Farnesyl pyrophosphate
  • HY-169162
    hBChE-IN-3

    		Carbonic Anhydrase Cholinesterase (ChE) Neurological Disease
    hBChE-IN-3 (compound 30) is a combination of carbonic anhydrase (CA) activator and cholinesterase (ChE) inhibitor with IC50 values of 7.4 and 1.9 nM for AchE and BchE, respectively. hBChE-IN-3 can be used in the study of neurodegeneration and psychiatric disorders .
    hBChE-IN-3
  • HY-130239A
    (±)14-HDHA

    (±)14-HDoHE; 14-hydroxy Docosahexaenoic acid; (±)14-HDoHE

    		 Drug Metabolite Neurological Disease
    (±)14-HDHA is the isomer of 14(S)-HDHA (HY-130239). 14(S)-HDHA is an oxygenation product of Docosahexaenoic acid (DHA). 14(S)-HDHA is a marker reflecting activation of a Docosahexaenoic acid carbon 14-lipoxygenation pathway .
    (±)14-HDHA
  • HY-100581
    CORM-3
    2 Publications Verification

    		 NF-κB NOD-like Receptor (NLR) Inflammation/Immunology
    CORM-3, a carbon monoxide-releasing molecule, attenuates NF-κB p65 nuclear translocation, reduces ROS generation and enhances intracellular glutathione and superoxide dismutase levels. CORM-3 reduces NLRP3 inflammasome activation .
    CORM-3
  • HY-W160298
    N-Cbz-7-Aminoheptanoic acid

    		Biochemical Assay Reagents Others
    N-Cbz-7-Aminoheptanoic acid is a six carbon linker containing an carboxylic acid (CO2H) group and a benzyl (Cbz) protecting group. The terminal carboxylic acid is reactive with primary amine groups in the presence of activators (e.g. EDC, or HATU) forming a stable amide bond. The benzyl protecting group can be removed via hydrogenolysis to form a free amine.
    N-Cbz-7-Aminoheptanoic acid
  • HY-130239S
    14(S)-HDHA-d5

    14(S)-HDoHE-d5

    		 Isotope-Labeled Compounds Drug Metabolite Neurological Disease
    14(S)-HDHA-d5 (14(S)-HDoHE-d5) is deuterium labeled 14(S)-HDHA. 14(S)-HDHA (14(S)-HDoHE) is an oxygenation product of Docosahexaenoic acid (DHA). 14(S)-HDHA is a marker reflecting activation of a Docosahexaenoic acid carbon 14-lipoxygenation pathway .
    14(S)-HDHA-d5
  • HY-13650
    Indisulam
    10+ Cited Publications

    E 7070

    		 Molecular Glues Carbonic Anhydrase Cancer
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .
    Indisulam
  • HY-136855
    MitoPBN

    		Endogenous Metabolite Metabolic Disease
    MitoPBN is a mitochondria-targeted antioxidant. It accumulates in the mitochondria following the generation of a mitochondrial membrane potential by succinate, an effect that is blocked by addition of the mitochondrial membrane potential uncoupler FCCP. MitoPBN inhibits superoxide activation of mitochondrial uncoupling protein 1 (UCP1), UCP2, and UCP3 when used at a concentration of 250 nM in vitro but does not react with superoxide. It traps hydroxyl (IC50=~77 μM) and carbon-centered radicals and inhibits the initiation of lipid peroxidation in isolated bovine heart mitochondria.
    MitoPBN
  • HY-13650R
    Indisulam (Standard)

    		Molecular Glues Carbonic Anhydrase Cancer
    Indisulam (Standard) is the analytical standard of Indisulam. This product is intended for research and analytical applications. Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .
    Indisulam (Standard)
  • HY-164125
    6-O-Bis[1-(2-nitrophenyl)-ethoxyphosphoryl]-D-trehalose

    		Ser/Thr Protease Others
    6-O-Bis[1-(2-nitrophenyl)-ethoxyphosphoryl]-D-trehalose is an important signaling molecule that regulates carbon utilization and growth in plants. 6-O-Bis[1-(2-nitrophenyl)-ethoxyphosphoryl]-D-trehalose releases T6P through light activation, which can stimulate starch synthesis and promote plant growth by inhibiting SnRK1, a protein kinase involved in energy conservation and survival. 6-O-Bis[1-(2-nitrophenyl)-ethoxyphosphoryl]-D-trehalose can be used to study plant growth and metabolism .
    6-O-Bis[1-(2-nitrophenyl)-ethoxyphosphoryl]-D-trehalose
  • HY-116673
    TTK21

    		Histone Acetyltransferase Neurological Disease
    TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .
    TTK21
  • HY-175021
    HDAC-IN-91

    		HDAC Carbonic Anhydrase Microtubule/Tubulin PARP Apoptosis Bcl-2 Family Caspase Cancer
    HDAC-IN-91 is a multiple inhibitor of HDAC (IC50 = 134.22 nM for HDAC1, 66.29 nM for HDAC2), carbonic anhydrase (CA) (KI = 72.03 nM for CA IX, 50.76 nM for XII), and tubulin polymerization ( IC50 = 2.56 μM). HDAC-IN-91 inhibits PARP1 and increases the Bax/Bcl-2 ratio. HDAC-IN-91 blocks the cell cycle at the G2/M phase and induces apoptosis through a mitochondrial apoptosis activation mechanism. HDAC-IN-91 can exert potent cytotoxic activity through tubulin polymerization inhibition. HDAC-IN-91 can be used in breast, colorectal, cervical and lung cancer research .
    HDAC-IN-91
  • HY-174232
    EGFR/CA-IX-IN-1

    		EGFR Carbonic Anhydrase Caspase Cancer
    EGFR/CA-IX-IN-1 (Compound 14) is a dual inhibitor against epidermal growth factor receptor (EGFR) and carbonic anhydrase IX (CA-IX) with IC50 values of 5.92 nM and 63 nM, respectively. EGFR/CA-IX-IN-1 shows strong cytotoxicity against breast cancer cells (MDA-MB-231, MCF-7) with IC50 values of 5.78 μM and 8.05 μM, respectively. EGFR/CA-IX-IN-1 inhibits the catalytic activity of CA-IX, up-regulates BAX/Bcl-2, activates caspases, and arrests the cell cycle at the G1 phase. EGFR/CA-IX-IN-1 is promising for research of breast cancer .
    EGFR/CA-IX-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: